Aspira Women’s Health (NASDAQ:AWH) Now Covered by StockNews.com

StockNews.com began coverage on shares of Aspira Women’s Health (NASDAQ:AWH) in a research report sent to investors on Sunday morning. The firm issued a hold rating on the stock.

Separately, Alliance Global Partners decreased their target price on Aspira Women’s Health from $7.00 to $5.50 and set a “buy” rating on the stock in a research report on Wednesday, August 14th.

Aspira Women’s Health Price Performance

Aspira Women’s Health stock opened at $0.89 on Friday. Aspira Women’s Health has a 1-year low of $0.67 and a 1-year high of $5.65. The company has a market cap of $14.83 million, a PE ratio of -0.74 and a beta of 1.44. The stock’s 50 day moving average price is $0.84 and its 200 day moving average price is $1.25.

Hedge Funds Weigh In On Aspira Women’s Health

A hedge fund recently bought a new stake in Aspira Women’s Health stock. Pine Valley Investments Ltd Liability Co bought a new stake in Aspira Women’s Health Inc. (NASDAQ:AWH) in the 3rd quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor bought 31,200 shares of the company’s stock, valued at approximately $25,000. Pine Valley Investments Ltd Liability Co owned about 0.19% of Aspira Women’s Health at the end of the most recent quarter. 12.19% of the stock is currently owned by institutional investors and hedge funds.

About Aspira Women’s Health

Aspira Women's Health Inc, together with its subsidiaries, discovers, develops, and commercializes of noninvasive AI-powered diagnostic tests for gynecologic diseases in the United States. The company's products include Ova1Plus, a qualitative serum test to assess the likelihood of malignancy in women with an ovarian adnexal mass; Overa, a biomarker test intended to maintain Ova1's high sensitivity; and OvaWatch, a laboratory developed tests to assist in the initial clinical assessment of malignancy risk in all women thought to have an indeterminate or benign adnexal mass.